Nancy E. Kohl

RheinMain University of Applied Sciences — Germany

Medicine · Health Sciences

52h-index12.4kcitations222works5.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(33), Protein Kinase Regulation and GTPase Signaling(31), Liver physiology and pathology(27), PI3K/AKT/mTOR signaling in cancer(23), Lung Cancer Treatments and Mutations(21)

Publications222 total

Supplementary Figures S1-S16 from NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
2025Open Access
Abstract B057: Preclinical intracranial activity of NVL-330, a selective HER2 tyrosine kinase inhibitor
Molecular Cancer Therapeutics·2025
Digital Movement Therapy for Axial Spondyloarthritis: A Randomized Controlled Trial on Clinical Outcomes, Usability, and Costs
2025· 1 citedOpen Access
POS0872 IMPROVING HEALTH OUTCOMES AND REDUCING HEALTHCARE COSTS THROUGH DIGITAL MOVEMENT THERAPY: A RANDOMIZED TRIAL
Annals of the Rheumatic Diseases·2025Open Access
Supplementary Figures S1-S17 from NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
2024Open Access
Data from NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
2024Open Access
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
Cancer Discovery·2024· 42 citedOpen Access
Abstract 1979: Preclinical characterization of NVL-330, a selective and brain penetrant HER2 tyrosine kinase inhibitor with broad activity on HER2 oncogenic alterations
Cancer Research·2024· 2 cited
Supplementary Figures S1-S16 from NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
2023Open Access
Data from NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
2023Open Access
Supplementary Figures S1-S16 from NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
2023Open Access
Data from NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
2023Open Access
Supplementary Data from First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
2023Open Access
Data from First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
2023Open Access
Data from First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
2023Open Access
Supplementary Methods from Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
2023Open Access
Supplementary Figures 1 through 7 and Supplementary Table 1 from Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
2023Open Access
Supplementary Data from First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
2023Open Access
Supplementary Methods, Figure Legends from First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
2023Open Access
Supplementary Methods from Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
2023Open Access
page 1 of 12Next →

Frequent Co-authors

W. Wayt Gibbs(17), Allen Oliff(13), Samuel Graham(10), Kelly Hamilton(9), George D. Hartman(9), Robert B. Lobell(9), S. J. DESOLMS(8), Carolyn A. Buser(8), Joseph P. Davide(7), Elaine Rands(7), Elizabeth A. Giuliani(6), Kenneth S. Koblan(6), Michael D. Schaber(6), Eileen S. Walsh(6), Frederick W. Alt(5), Scott D. Mosser(5), Ronald E. Diehl(5), Hans E. Huber(5), Lenora J. Davis(4), Charles A. Omer(4)